Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine
Disease Category: Breast Cancer
Location: United States, WA
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
This phase II trial is studying how well giving paclitaxel albumin-stabilized nanoparticle formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with metastatic breast cancer.
Patient Inclusion Criteria:
Patient Exclusion Criteria:
CW ID: 183316
Date Last Changed:
September 17, 2012
Christine Goetz, BA; CCRCMultiCare Health System314 Martin Luther King, Jr. Way, Suite 402Tacoma, WA 98405Phone: 253-403-7193
MultiCare Health System
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2017 CenterWatch.